NCT Number: NCT05046717
The lack of ADAMTS13 is the only biological marker that is specific for aTTP diagnosis8 and the assessment of ADAMTS13 is of clinical importance because it is essential for the rapid differential diagnosis between aTTP and other TMA. Furthermore, monitoring of ADAMTS13 activity is useful to ensure biological remission (ADAMTS13 levels > 10%) as well as predicting relapses.
Due to the high mortality rate of aTTP, treatment should be started as soon as the disease is suspected, sometimes even before confirmation with the ADAMTS13 test results. This situation may lead to misdiagnose some patients and leave them without the appropriate treatment. In conclusion, ADAMTS13 activity assay is crucial for an early diagnosis and optimal management of acute aTTP and any delay in ADAMTS13 results will have a negative impact on the diagnosis, treatment and prognosis of the patient.
There are currently 2 techniques available for the ADAMTS13 activity determination, the fluorescence resonance energy transfer (FRET) and the Technozym chromogenic enzyme-linked immunosorbent assay (ELISA). Both are considered reference methods but they require considerable skill because they are highly manual and this increases the risk of error. Furthermore, these methods are time-consuming, not widely available and, in case of the ELISA method, it requires a new calibration at each run. The inter-laboratory variability is also a challenge and therefore a validation and/or interpretation method could be needed.
Recently, a new and first fully automated HemosIL AcuStar ADAMTS13 Activity assay (Instrumentation Laboratory, Bedford, Massachusetts, United States) has been developed. HemosIL AcuStar ADAMTS13 Activity assay is a two steps chemiluminescent immunoassay (CLIA) with an analytical time of 33 minutes for the quantitative measurement of ADAMTS13 activity in human-citrated plasma on the ACL AcuStar analyser. The immunoassay uses the GST-VWF73 substrate in combination with magnetic particles for rapid separation and chemiluminescence technology detection. The ADAMTS13 present in the plasma sample cleavages the GST-VWF73 substrate and the detection of the generated fragments is based upon an isoluminol-labelled monoclonal antibody that specifically reacts with the cleaved peptide. The emitted light is proportional to the ADAMTS13 activity in the sample.
This new ADAMTS13 assay method has been compared with the other two available techniques in two different studies. First, Favresse et al. published the results of the comparison between Technozym activity ELISA assay and the new HemosIL AcuStar chemiluminescent assay. On the other hand, Valsecchi et al. have recently published the results of validation of this new technique in comparison with ELISA and FRETS in 176 samples. Both studies conclude that the new chemiluminescent ADAMTS13 activity assay showed a good correlation and excellent clinical performance for the diagnosis of severe ADAMTS13 deficiency with the FRETS-VWF73 assay and a commercial ELISA when considering only ADAMTS13 activity values below 10% (the internationally accepted cut-off for a diagnosis of severe ADAMTS13 deficiency typical of aTTP). Finally, Stratmann et al. have just published another study comparing the HemosIL AcuStar chemiluminescent assay with two commercially available ADAMTS13 assay kits using 24 paired test samples derived from 10 consecutively recruited patients13 and their results corroborate the previously published data suggesting that the AcuStar assay could be a valuable and accurate tool for ADAMTS13 activity testing and aTTP diagnostic.
In this context, a unique opportunity to validate this new technique is generated, both retrospectively with our already available data from frozen samples and also in the context of a large prospective study. This will be the first study worldwide testing HemosIL AcuStar method in real clinical practice aTTP population (Spanish and Portuguese aTTP populations) with the aim to standardize the diagnosis and follow-up methodology for the disease.
This study is active but is not currently recruiting participants.
Notify Me0 year–99 year
All sexes
Observational
Centro Hospitalar e Universitario de Coimbra, Coimbra, Coimbra District, Portugal
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:
Three kits will be used with all patients.
Time frame: At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL
Time frame: At follow up (10 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL
Time frame: At follow up (30 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL
Time frame: At follow up (60 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL
Time frame: At follow up (90 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL
Time frame: At follow up (180 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL
Time frame: At follow up (365 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Correlation of a new diagnostic test, HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS in the measurement of activity and antibody of ADAMTS13 in IU/mL
Time frame: At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the concordance of classification of aTTP patients at diagnosis based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (10 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (30 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (60 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (90 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (180 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (365 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the concordance of classification of aTTP patients based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (10 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (30 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (60 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (90 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (180 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At follow up (365 days) of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
To evaluate the sensitivity and specificity of classification of aTTP patients visits based on HemosIL AcuStar chemiluminescent assay, in comparison with ELISA and/or FRETS.
Time frame: At diagnosis of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.
Time frame: At follow up (10 days)
Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.
Time frame: At follow up (30 days)
Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.
Time frame: At follow up (60 days)
Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.
Time frame: At follow up (90 days)
Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.
Time frame: At follow up (180 days)
Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.
Time frame: At follow up (365 days)
Describe clinical characteristics of patients with TMA at the diagnosis and those with aTTP at the diagnosis and follow up based on ADAMTS13 cut-off < 10%.
Fundación Española de Hematología y Hemoterapía
Other
Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura: a Collaborative Study Proposal of the Spanish Apheresis Group (GEA) in Collaboration With the Spanish Foundation of Hematology and Hemotherapy (FEHH)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04985318
Acquired Thrombotic Thrombocytopenic Purpura, Blood Coagulation Disorders
Cologne, Germany
View Trial DetailsNCT05876221
Acquired Thrombotic Thrombocytopenic Purpura, Blood Coagulation Disorders
Cologne, Germany
View Trial DetailsNCT06794008
ANCA-associated Vasculitis, Acquired Thrombotic Thrombocytopenic Purpura
Beijing, Beijing Municipality, China
View Trial DetailsNCT02553317
Acquired Thrombotic Thrombocytopenic Purpura, Blood Coagulation Disorders
Birmingham, Alabama, United States
View Trial Details